Hostname: page-component-7b7567c8c-jswmv Total loading time: 0 Render date: 2026-11-15T23:27:00.974Z Has data issue: false hasContentIssue false

Characteristics of Pseudomonas aeruginosa infection in intensive care unit before (2007–2010) and after (2011–2014) the beginning of an antimicrobial stewardship program

Published online by Cambridge University Press:  29 April 2024

Alessio Strazzulla*
Affiliation:
Internal and General Medicine Unit, Groupe Hospitalier Sud Ile de France, Melun, France
Vladimir Adrien
Affiliation:
Infectious Diseases Unit, Groupe Hospitalier Sud Ile de France, Melun, FranceDepartment of Infectious and Tropical Diseases, Avicenne Hospital, AP-HP, Université Sorbonne Paris Nord, Bobigny, France
Segla Robert Houngnandan
Affiliation:
Internal and General Medicine Unit, Groupe Hospitalier Sud Ile de France, Melun, France
Sandra Devatine
Affiliation:
Infectious Diseases Unit, Groupe Hospitalier Sud Ile de France, Melun, France
Ouerdia Bahmed
Affiliation:
Internal and General Medicine Unit, Groupe Hospitalier Sud Ile de France, Melun, France
Sarra Abroug
Affiliation:
Internal and General Medicine Unit, Groupe Hospitalier Sud Ile de France, Melun, France
Sarra Hamrouni
Affiliation:
Internal and General Medicine Unit, Groupe Hospitalier Sud Ile de France, Melun, France
Mehran Monchi
Affiliation:
Intensive Care Unit, Groupe Hospitalier Sud Ile de France, Melun, France
Sylvain Diamantis
Affiliation:
Internal and General Medicine Unit, Groupe Hospitalier Sud Ile de France, Melun, FranceInfectious Diseases Unit, Groupe Hospitalier Sud Ile de France, Melun, FranceEA 7380 Dynamic, Université Paris Est Créteil, EnvA, USC ANSES, Créteil, France
*
Corresponding author: Alessio Strazzulla; Email: alessio.strazzulla@ghsif.fr

Abstract

Objectives:

To investigate the factors associated with Pseudomonas aeruginosa isolates in intensive care unit (ICU) before and after an antimicrobial stewardship program.

Materials:

Monocentric retrospective cohort study. Patients admitted to the ICU in 2007–2014 were included. Characteristics of P. aeruginosa patients were compared to overall ICU population. Clinical and microbiological characteristics of P. aeruginosa patients before (2007–2010) and after (2011–2014) the beginning of the AMP were compared.

Results:

Overall, 5,263 patients were admitted to the ICU, 274/5,263 (5%) had a P. aeruginosa isolate during their staying. In 2011–2014, the percentage P. aeruginosa isolates reduced (7% vs 4%, P ≤ .0001). Patients with P. aeruginosa had higher rates of in-hospital death (43% vs 20%, P < .0001) than overall ICU population. In 2011–2014, rates of multidrug-resistant (11% vs 2%, P = .0020), fluoroquinolone-resistant (35% vs 12%, P < .0001), and ceftazidime-resistant (23% vs 8%, P = .0009) P. aeruginosa reduced. Treatments by fluoroquinolones (36% vs 4%, P ≤ .0001), carbapenems (27% vs 9%, P = .0002), and third-generation cephalosporins (49% vs 12%, P ≤ .0001) before P. aeruginosa isolation reduced while piperacillin (0% vs 13%, P < .0001) and trimethoprim-sulfamethoxazole (8% vs 26%, P = .0023) increased. Endotracheal intubation reduced in 2011–2014 (61% vs 35%, P < .0001). Fluoroquinolone-resistance was higher in patients who received endotracheal intubation (29% vs 17%, P = .0197). Previous treatment by fluoroquinolones (OR = 2.94, P = .0020) and study period (2007–2010) (OR = 2.07, P = .0462) were the factors associated with fluoroquinolone-resistance at the multivariate analysis.

Conclusions:

Antibiotic susceptibility in P. aeruginosa isolates was restored after the reduction of endotracheal intubation, fluoroquinolones, carbapenems, and third-generation cephalosporins and the increased use of molecules with a low ecological footprint, as piperacillin and trimethoprim-sulfamethoxazole.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Table 1.Characteristics of the population

Figure 1

Table 2.Characteristics of patients with Pseudomonas aeruginosa isolates

Figure 2

Table 3.Characteristics of patients with Pseudomonas aeruginosa isolates

Figure 3

Table 4.Resistance to fluoroquinolones among Pseudomonas aeruginosa isolates from patients receiving endotracheal intubation

Figure 4

Table 5.Multivariate analysis of factors associated with fluoroquinolone resistance in Pseudomonas aeruginosa isolates

Figure 5

Table 6.Multivariate analysis of factors associated with presence of multi drug resistant Pseudomonas aeruginosa isolates